|Publication number||US3927193 A|
|Publication date||Dec 16, 1975|
|Filing date||May 18, 1973|
|Priority date||May 18, 1973|
|Publication number||US 3927193 A, US 3927193A, US-A-3927193, US3927193 A, US3927193A|
|Inventors||Hansen Hans John, Primus Frederick James|
|Original Assignee||Hoffmann La Roche|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (5), Referenced by (80), Classifications (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent [1 1 Hansen et a].
In] 3,927,193 [4 1 Dec. 16, 1975 1 LOCALIZATION OF TUMORS BY RADIOLABELLED ANTIBODIES [75) Inventors: Hans John Hansen, Allendale;
- Frederick James Primus, Waldwick,
both of NJ. 73 Assignee: nofiiimn-La Roche Inc., Nutley,
[221 Filed: May 18, 1973  Appl. No.: 361,718
 US. Cl 424/1; 250/303  Int. CL. A6IK 43/00; GOIT 1/161  Field of 424/1, 9, 12; 23/230 B;
 References Cited UNITED STATES PATENTS 3,663,684 5/1972 Freedman et al 424/1 3,697,638 10/1972 Hansen 424/1 3,718,737 2/1973 Penn 424/1 3,735,001 5/1973 McRae et a1. 424/1 3,812,245 5/1974 Dugan 424/1 OTHER PUBLICATIONS Nuclear Science Abstracts, Vol. 24, No. 23, Dec. 15, 1970, p. 4722, Item No. 48,360.
Nuclear Science Abstracts, Vol. 26, No. 22, Nov. 30, 1972, p. 5345, Item No. 55,505.
Chemical Abstracts, Vol. 77, No. 1, July 3, 1972, p. 342, Item No. 3636n.
Chemical Abstracts, Vol. 77, No. 23, Nov. 30, 1972, p. 274, Item No. 150403.
Chemical Abstracts, V01. 78, No. 5, Feb. 5, 1973, p. 338, Item No. 27647p.
Chemical Abstracts, Vol. 78, No. 15, Apr. 16, 1973, p. 330, Item No. 95838b.
Primary Examiner-Benjamin R. Padgett Assistant Examiner Christine M. Nucker Attorney, Agent, or Firm-Samuel L. Welt; Jon S. Saxe; Gerald S. Rosen 1 1 ABSTRACT A method of utilizing radiolabelled antibodies to carcinoembryonic antigens for determining the site of tumors which produce or are associated with carcinoembryonic antigen is disclosed.
3 Claims, No Drawings LOCALIZATION OF TUMORS BY RADIOLABELLED ANTIBODIES BACKGROUND Carcinoembryonic antigen (CEA) is a mixture of several components, at least two of which have antigenic activity which is associated with human carcinoma. Methods such as those described in US. Pat. Nos. 3,663,684 and 3,697,638 have been developed for detecting the presence of CEA circulating in human blood. These known processes, however, do not provide a means for pinpointing the location and the source of the CEA. There is thus a need for a diagnostic method which will be satisfactory for locating the site of the tumor which produces or is associated with CEA.
DESCRIPTION OF THE INVENTION We have discovered that when a measured amount of radiolabelled antibody specific to carcinoembryonic antigen is administered parenterally, preferably by intravenous injection, the location of carcinoma tumors which either produce or are associated with carcinoembryonic antigen can be determined. As used herein carcinoembryonic antigen (CEA) includes both a mixture of antigenic components with CEA activity or a single such component.
In order to localize the tumor, radiolabelled antibody specific to CEA is injected into the subject and during the following eight days the subject is scanned with a photoscanning device which locates the sites at which the radiolabelled antibody is complexed with CEA. It is at these sites where the tumors associated with CEA are located.
The radioisotope suitable for use in this invention is an atom which does not interfere with the acitivity of the antibody. is sufficiently stable to be detected after complexation with CEA. has a half-life of sufficient duration to enable detection within 8 days and is phar maceutically inert, i.e., non-toxic and without pharmacological effect, in the amounts used and has a sufficient gamma intensity to be detected readily by the photoscanning techniques presently in use, i.e., 100 to 500 Kev (thousand electron volts). [t has been found that while P or are suitable for use in localizing tumors, is preferred for use in humans because of its favorable halflife. As a practical matter, any radioisotope with a half-life up to about eight days and a gamma emission of 10 to 5000 Kev is suitable for use.
When radioactive iodine is used, the antibody is radio-iodinated by the procedure of Greenwood, Hunter and Glover, Biochem J. 89 ll4-l23. (I963) as modified by McConahy and Dixon. Int. Arch. Allergy 29 l85-l89, 1966. The reaction is effected, for example, by using a 100 a! reaction mixture containing 50 ul. of chloramine-T (sodium p-toluenesulfochloramine); 40 ul. of goat anti-CEA lmmunoglobulin G in a phosphate buffer of pH 7.5 (10 mg./ml. 0.05 M phosphate, pH 7.5) and 2 mCi of I or 1" in the form of Nal. The reaction takes place in about L5 minutes at room temperature and is stopped by the addition of sodium metabisulfite. The radioiodinated product can be separated from the unreacted radioisotope by chromatography in a cross-linked dextran gel column. e.g.. Sephadex G-ZS or Sephadex G- l by eluting with Tris-NaCl or PBS. The labelled antibody is stabilized by mixing with a carrier protein such as serum or aqueous human albumin. The resulting product has a specific activity of 2 about 4 to 6 Ci/ ug. This specific activity can be modified by altering the reaction conditions. The level of the specific activity to be used should be below that which would interfere with the immunological activity of the anti-CEA antibody. It has been found that about 4 to 50 uCi/ug. are suitable with 4 to 6 uCi/ g preferred.
The antibody utilized is important to the operability of the process since it must be CEA specific and must be amenable to radiolabelling with sufficient activity per unit weight to result in a readily demonstrable effeet.
It has been found that animal sources used for producing the antibodies vary greatly from species to species and between animals within a species in their ability to produce large concentrations of highly specific CEA antibodies per unit volume of serum. It has been found that rabbits and goats are suitable. with goats preferred. The antibodies are made by immunizing the animals against purified CEA. such as the CEA produced by the process disclosed in US. Pat. No. 3,697,638, and after a suitable time interval obtaining serum from the animal. The antibodies are isolated from the serum by column chromatography using, for example. Sephadex (1-200 (Pharmacia, Uppsala, Swe den) and diethylaminoethyl (DEAE) cellulose (Whatman DE 52, H. Reeve Angel lnc., Clifton, N.J.). The purity and specificity of the antibodies is checked by immunoelectrophoresis and immunodiffusion.
The radiolabelled antibody is administered to the subject parenterally, preferably l.V.. in an amount sufficient to provide radioactivity which can be readily detected. but not so much that the radioactivity is unsafe for the patient. This is accomplished utilizing a parenteral formulation containing about 300 to I000 uCi per ml. Generally about I to 2 ml. are administered. A suitable formulation for injection contains a phosphate buffer at pH 7.0 and a stabilizer for the radiolabelled antibody.
In order to demonstrate that the radiolabelled antibody does localize tumors which produce or are associated with CEA, hamsters having such tumors implanted are simultaneously injected with an equal mixture of anti-CEA antibody labelled with iodine-I25 and normal non-specific immunoglobulin G labelled with iodine-l3]. After a suitable time, generally from I to 8 days, the hamsters are sacrificed and various organs as well as blood are tested for radioactivity and the percent of injected dose found per gram of tissue is calcu lated for each isotope. By means of this technique, i.e., the paired-labelled antibody technique. there is demonstrated that tumors are preferentially radiolabelled by the labelled CEA antibody whereas the non-specific antibody is distributed randomly. This is shown by the localization ratio.
The following examples illustrate the invention.
EXAMPLE 1 Radioiodination of Antibodies to CEA a. Two mCi of l in the form of Nal are mixed with 40 ul. of goat anti-CEA lgG (ll) mg./ml. of 0.05 M phosphate, pH 7.5). Fifty 1.1.1. of Chloramine-T (3 mg/ml. phosphate buffer) are added and the mixture allowed to react for [.5 minutes at room temperature. Fifty ,ul. of Na- S Q, (6 mg./ml. phosphate buffer) is added to stop the reaction. The unbound radioisotpe is separated by filtration over a 2.6 X 35 cm Sephadex G-lUU column employing Tris-NaCl as the eluting 3 buffer. The iodinated antibody is collected and stabilized in the carrier protein 5% aqueous human albumin (Albuspan Parke. Davis).
The specific activity of the product is 4-6 uCi/ug.
b. Two mCi of l in the form of Nal are mixed with 40 ul. of goat anti-CEA lgG l mg./ml. 0.05 M phosphate, pH 7.5). Fifty pl. of Chloramine-T (3 mg./ml. phosphate buffer) are added and the mixture allowed to react for L minutes at room temperature. The unbound radioisotope is separated by filtration over a 2.6 X 35 cm. Sephadex G- l00 column employing Tris- NaCl as the eluting buffer. The iodinated antibody is collected and stabilized in the carrier protein 5% aqueous human albumin (Albuspan Parke, Davis).
The specific activity of the product is 4-6 uCi/ug. For use in the paired labelled antibody technique normal goat lgG is radioiodinated in the same manner using it in place of the anti-CEA lgG.
EXAMPLE 2 CEA isolated from liver metastasis originating as adenocarcinoma of the colon was purified by column chromatography as described in US. Pat. No. 3,697,638. Goat antiserum to the thus prepared CEA was prepared by the so. injection into 2 sites of 500 ugm. of CEA in 1 ml. phosphate-buffered saline (PBS) containing 1 mg. of methylated bovine serum albumin and an equal volume of complete Freunds adjuvant. CEA was injected every 2 weeks for a total of 5 injections. The animals were terminally bled days following the final injection.
Twenty ml. of the resulting goat anti-CEA antiserum is dialyzed against 0.1 M Tris-HCl, pH 7.0, containing 0.15 M NaCl and 0.02% sodium azide and applied to a 5 X 90 cm cross-linked dextran gel column (Sephadex (3-200) equilibrated with the same buffer and maintained at 4C. Isolated fractions are tested for anti-CEA activity by the radioimmunoassay of Hansen (US. Pat. No. 3,697,638) and the material eluting between 690 and 930 ml. of' elution volume is pooled and concentrated by pressure filtration over a Diaflo UM I00 ultrafilter (retains l00,000 MW or greater). The concentrated material was dialyzed against 0.0l M phosphate buffer, pH 8.0, and applied to a 2.6 X 25 cm. diethylaminoethyl (DEAE)-cellulose column equilibrated with the same buffer. Following elution with l liter of starting buffer. the anti-CEA IgG appearing between 260 to 600 ml. of elution volume was pooled, dialyzed against distilled water, and lyophilized. Immunoelectrophoresis and immunodiffusion were performed to evaluate the purity of the anti-CEA IgG.
EXAMPLE 3 An injectable formulation was prepared containing 0.200 gms. of radiolabelled anti-CEA antibody with an activity of 400 uCi/ml. of a phosphate buffered saline solution at pH 7.0 containing, by weight, 0.5 to 2.5% hepatitis free-human albumin.
EXAMPLE 4 Demonstration of Localization of Tumors Male Syrian hamsters weighing 50-60 gms., were heterografted intramuscularly with a C EA producing human Signet-ring cell carcinoma of the colon. designated in the laboratory as GW-39. At the time of transplantation, 2.5 mg. of cortisone acetate was given subcutaneously. The resulting tumor-bearing hamsters were administered an intracardial injection of the radiolabelled antibody and normal lgG mixture 1-4 weeks after implantation of tumor. The anti-CEA antibody and normal IgG were labelled with l and "l. respectively. The radioactivities were mixed 1: l on an activity basis and sterilely filtered. l0-l2 uCi of each were given in a final volume of 0.2-0.3 ml. Animals were administered Lugols solution (a stable Kl-l aqueous solution) in their drinking water to block thyroid uptake. At timed intervals, each animal was exsanguinated by cardiac puncture and various organs (liver, spleen, kidney, lung. stomach, muscle, tumor) were removed and radioactivity was determined in each organ as well as in 1 ml. of blood using a gamma scintillation counter. Using appropriately diluted injection mixture standards, the percent of injected dose found per gram of tissue was calculated for each radioisotope. In addition, a localization ratio was derived using the formula:
Anti -CEA Antibody/Normal lgG recovered in tissue Anti-CEA Antibody/Normal lgG injected The level of significance between tumors and reference tissues was calculated by the Students t-test.
The results showing the tumor localization ratio at different time intervals after injection as set forth in the following Table:
TABLE I Localization Ratio Obtained in Tumor Following Injection of Anti-CEA Normal lgG Mixture Tumor 1 Standard Tumor Day After Localization Error Wt. Gms. Injection Ratio (S.E.] S.E.
l l.6l5l .0355 0.49 t 0.33 2 l.9607 .0826 0.58 t 0.32 4 2.4825 .l289 0.94 i 0.46 6 3.5392 .2l56 l.2 0.72 8 4.l434 .6506 2.23 1 l 2 Table 2 Tumor/Blood Ratios Obtained After Injection of I' Labelled Anti-CEA Antibody and l Labelled Normal Antibody Antibody Anti-CEA Antibody Normal Antibody Days After Tumor/Blood Tumor/Blood Injection Ratio Ratio l .8l32 .4866 2 .9960 .5330 4 l.l420 .5080 6 l.75l6 .5800 8 2.3016 .5350
I. A method for determining the location of a tumor which either produces or is associated with carcinoem- 6 resulting uptake of radiolabelled antibody by said tumor.
2. The method of claim 1 wherein the antibody is radiolabelled with iodinel 3 l.
3. The method of claim I wherein the subject is injected intravenously.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3663684 *||Jun 1, 1970||May 16, 1972||Hoffmann La Roche||Carcinoembryonic antigen and diagnostic method using radioactive iodine|
|US3697638 *||Apr 12, 1971||Oct 10, 1972||Hoffmann La Roche||Antigens|
|US3718737 *||Oct 20, 1967||Feb 27, 1973||H Penn||Process of treating bile and novel iodine-131 complex|
|US3735001 *||May 24, 1972||May 22, 1973||Atomic Energy Commission||Technetium bone scanning medium|
|US3812245 *||Aug 21, 1972||May 21, 1974||Research Corp||Novel compositions for radiotracer localization of deep vein thrombi|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4132769 *||Oct 28, 1975||Jan 2, 1979||Osther Kurt B||Cancer antigen, cancer therapy, and cancer diagnosis|
|US4152410 *||Sep 1, 1976||May 1, 1979||Eisai Co., Ltd.||Diagnosis reagent for neoplasm and method for diagnosis of neoplasm|
|US4303636 *||May 12, 1978||Dec 1, 1981||Gordon Robert T||Cancer treatment|
|US4323546 *||May 14, 1979||Apr 6, 1982||Nuc Med Inc.||Method and composition for cancer detection in humans|
|US4331647 *||Mar 3, 1980||May 25, 1982||Goldenberg Milton David||Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers|
|US4348376 *||Mar 3, 1980||Sep 7, 1982||Goldenberg Milton David||Tumor localization and therapy with labeled anti-CEA antibody|
|US4361544 *||Mar 3, 1980||Nov 30, 1982||Goldenberg Milton David||Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers|
|US4444744 *||Sep 3, 1982||Apr 24, 1984||Goldenberg Milton David||Tumor localization and therapy with labeled antibodies to cell surface antigens|
|US4460561 *||Sep 8, 1982||Jul 17, 1984||Goldenberg M David||Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers|
|US4618577 *||Feb 9, 1983||Oct 21, 1986||The Regents Of The University Of California||Human-human hybridoma, CLNH5|
|US4837003 *||Sep 13, 1984||Jun 6, 1989||Mallinckrodt, Inc.||Radiolabeled antibody fragments|
|US5130116 *||May 29, 1990||Jul 14, 1992||Centocor, Inc.||Radiotherapeutic immunoconjugates labeled with iodine-125|
|US5256395 *||Sep 10, 1987||Oct 26, 1993||Immunotech Partners||Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells|
|US5273743 *||Dec 13, 1991||Dec 28, 1993||Hybritech Incorporated||Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent|
|US5364613 *||Jan 16, 1990||Nov 15, 1994||Sieving Paul F||Polychelants containing macrocyclic chelant moieties|
|US5670132 *||Sep 20, 1994||Sep 23, 1997||Immunomedics, Inc.||Modified radioantibody fragments for reduced renal uptake|
|US5697902 *||Jun 1, 1995||Dec 16, 1997||Immunomedics, Inc.||Method for imaging and treating organs and tissues|
|US5776093 *||Apr 7, 1992||Jul 7, 1998||Immunomedics, Inc.||Method for imaging and treating organs and tissues|
|US5776094 *||Jun 1, 1995||Jul 7, 1998||Immunomedics, Inc.||Method and kit for imaging and treating organs and tissues|
|US5776095 *||Jun 1, 1995||Jul 7, 1998||Immunomedics, Inc.||Method and kit for imaging and treating organs and tissues|
|US6013772 *||Jun 6, 1995||Jan 11, 2000||Bayer Corporation||Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays|
|US6022958 *||Jun 6, 1995||Feb 8, 2000||Bayer Corporation||cDNAs coding for members of the carcinoembryonic antigen family|
|US6051229 *||May 18, 1995||Apr 18, 2000||The Regents Of The University Of California||Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions|
|US6051387 *||Jun 7, 1995||Apr 18, 2000||The Regents Of The University Of California||Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies|
|US6051693 *||Jun 7, 1995||Apr 18, 2000||The Regents Of The University Of California||CLNH11-specific antibodies|
|US6274118||Apr 5, 2000||Aug 14, 2001||Nordion International Inc.||Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen|
|US6361774||Sep 17, 1999||Mar 26, 2002||Immunomedics, Inc.||Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug|
|US6458933||May 19, 1999||Oct 1, 2002||Immunomedics, Inc.||Therapeutic using a bispecific antibody|
|US6759243||Dec 6, 2000||Jul 6, 2004||Board Of Trustees Of The University Of Illinois||High affinity TCR proteins and methods|
|US6899864||Apr 1, 2002||May 31, 2005||Immunomedics, Inc.||Morpholino imaging and therapy|
|US7011812||Jun 20, 2000||Mar 14, 2006||Immunomedics, Inc.||Targeted combination immunotherapy of cancer and infectious diseases|
|US7053210||Jul 2, 2003||May 30, 2006||Health Research, Inc.||Efficient synthesis of pyropheophorbide a and its derivatives|
|US7230084||Sep 30, 2002||Jun 12, 2007||Immunomedics, Inc.||Therapeutic using a bispecific antibody|
|US7300644||Feb 10, 2003||Nov 27, 2007||Immunomedics, Inc.||Targeted combination immunotherapy|
|US7419659||Dec 5, 2002||Sep 2, 2008||Ucb Pharma S.A.||Expression control using variable intergenic sequences|
|US7470429||Feb 6, 2002||Dec 30, 2008||Immunomedics, Inc.||Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug|
|US7501509||Jun 14, 2006||Mar 10, 2009||Health Research, Inc.||Water soluble tetrapyrollic photosensitizers for photodynamic therapy|
|US7514066||Oct 15, 2007||Apr 7, 2009||Immunomedics, Inc.||Targeted combination immunotherapy of cancer and infectious diseases|
|US7569357||Feb 20, 2004||Aug 4, 2009||Board Of Trustees Of The University Of Illinois||High affinity TCR proteins and methods|
|US7811570||Sep 20, 2005||Oct 12, 2010||Immunomedics, Inc.||Method of affecting a function of or ablating a non-malignant cell|
|US7820143||Feb 19, 2009||Oct 26, 2010||Health Research, Inc.||Water soluble tetrapyrollic photosensitizers for photodynamic therapy|
|US7897140||Jun 30, 2006||Mar 1, 2011||Health Research, Inc.||Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents|
|US7931890||Aug 25, 2005||Apr 26, 2011||Immunomedics, Inc.||Targeted combination immunotherapy of cancer and infectious diseases|
|US8038983||Jul 29, 2004||Oct 18, 2011||Immunomedics, Inc.||Fluorinated carbohydrate conjugates|
|US8409577||Jun 12, 2007||Apr 2, 2013||Emergent Product Development Seattle, Llc||Single chain multivalent binding proteins with effector function|
|US8466261||Mar 28, 2012||Jun 18, 2013||Immunomedics, Inc.||Therapeutic using a bispecific antibody|
|US8853366||Feb 14, 2012||Oct 7, 2014||Emergent Product Development Seattle, Llc||Binding domain-immunoglobulin fusion proteins|
|US9101609||Apr 13, 2009||Aug 11, 2015||Emergent Product Development Seattle, Llc||CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof|
|US20010018186 *||Apr 11, 2001||Aug 30, 2001||Hirth Klaus Peter||Method for molecular diagnosis of tumor angiogenesis and metastasis|
|US20020114808 *||Feb 6, 2002||Aug 22, 2002||Immunomedics, Inc.||Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug|
|US20020165149 *||Dec 10, 2001||Nov 7, 2002||Kranz David M.||Mutated class II major histocompatibility proteins|
|US20030003051 *||Jun 11, 2002||Jan 2, 2003||Inverardi Luca A.||Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations|
|US20030003102 *||Apr 1, 2002||Jan 2, 2003||University Of Massachusetts||Morpholino imaging and therapy|
|US20030103982 *||Sep 30, 2002||Jun 5, 2003||Immunomedics, Inc.||Therapeutic using a bispecific antibody|
|US20030232011 *||Feb 10, 2003||Dec 18, 2003||Immunomedics, Inc.||Targeted combination immunotherapy|
|US20050136001 *||Jul 29, 2004||Jun 23, 2005||Immunomedics, Inc.||Fluorinated carbohydrate conjugates|
|US20050260131 *||May 20, 2004||Nov 24, 2005||General Electric Company||Pharmaceuticals for enhanced delivery to disease targets|
|US20060002855 *||Aug 25, 2005||Jan 5, 2006||Immunomedics, Inc.||Targeted combination immunotherapy of cancer and infectious diseases|
|US20060067885 *||Sep 20, 2005||Mar 30, 2006||Immunomedics, Inc.||Method and kit for imaging and treating organs and tissues|
|US20060104949 *||Dec 5, 2002||May 18, 2006||Popplewell Andrew G||Expression Control Using Variable Intergenic Sequences|
|US20080031813 *||Oct 15, 2007||Feb 7, 2008||Griffiths Gary L||Targeted Combination Immunotherapy of Cancer and Infectious Diseases|
|US20110117105 *||Jan 10, 2011||May 19, 2011||Immunomedics, Inc.||Method of treating immune disease using b-cell antibodies|
|USRE32417 *||Feb 3, 1986||May 12, 1987||Summa Medical Corporation||Radiolabeled antibody to anti-tumor associated antigen and process|
|USRE43274||Jan 23, 2009||Mar 27, 2012||Health Research, Inc.||Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy|
|DE2828941A1 *||Jun 30, 1978||Jan 10, 1980||Robert Thomas Gordon||Mittel zur behandlung von krebs|
|EP0035265A2 *||Mar 2, 1981||Sep 9, 1981||Milton David Goldenberg||Agent for tumor localization and therapy with labeled antibodies and antibody fragments|
|EP0035265A3 *||Mar 2, 1981||Apr 7, 1982||Milton David Goldenberg||Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers|
|EP0090025A1 *||Sep 20, 1982||Oct 5, 1983||Roberto Luis Dr. Ceriani||Specific mammary gland labelling|
|EP0090025A4 *||Sep 20, 1982||Jan 12, 1984||Roberto Luis Ceriani||Specific mammary gland labelling.|
|EP2042869A2||Dec 6, 2000||Apr 1, 2009||Board Of Trustees Of The University Of Illinois||High affinity TCR proteins and methods|
|EP2287185A2||Dec 6, 2000||Feb 23, 2011||Board Of Trustees Of The University Of Illinois||High affinity TCR proteins and methods|
|EP2336775A2||Dec 6, 2000||Jun 22, 2011||Board Of Trustees Of The University Of Illinois||High affinity TCR proteins and methods|
|EP2418223A2||Jun 12, 2007||Feb 15, 2012||Emergent Product Development Seattle, LLC||Single-chain multivalent binding proteins with effector function|
|WO1981002522A1 *||Mar 2, 1981||Sep 17, 1981||M Goldenberg||Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers|
|WO1989012465A1 *||Jun 13, 1989||Dec 28, 1989||Schering Aktiengesellschaft||A method for the visual display of tumors using monoclonal antibodies|
|WO1993019668A1 *||Apr 2, 1993||Oct 14, 1993||Immunomedics, Inc.||Method and kit for imaging and treating organs and tissues|
|WO1996039937A1 *||Jun 7, 1996||Dec 19, 1996||The Regents Of The University Of California||Microfabricated devices for diagnostic applications|
|WO2003074569A2||Mar 3, 2003||Sep 12, 2003||Immunomedics, Inc.||Bispecific antibody point mutations for enhancing rate of clearance|
|WO2004074434A2||Feb 2, 2004||Sep 2, 2004||Immunomedics, Inc.||Methods and compositions for administering therapeutic and diagnostic agents|
|WO2011044186A1||Oct 6, 2010||Apr 14, 2011||The Board Of Trustees Of The University Of Illinois||Human single-chain t cell receptors|
|U.S. Classification||424/1.49, 250/303|
|International Classification||A61K51/10, A61K51/02|
|Cooperative Classification||A61K51/1048, A61K2123/00|